Abstract | PURPOSE: METHODS: In this phase III, double-blind, randomized, placebo-controlled, multicenter trial, 207 patients (age 6-17 years) with partial epilepsy, receiving one or two antiepileptic drugs, were randomized to receive adjunctive zonisamide or placebo. Zonisamide was initiated at 1 mg/kg/day, titrated to a target dose of 8 mg/kg/day over 8 weeks (one down-titration permitted), and maintained for 12 weeks. The primary efficacy end point was the proportion of responders (≥ 50% seizure frequency reduction from baseline) during the 12-week maintenance period. Safety/tolerability assessments included the incidence of treatment-emergent adverse events (TEAEs). KEY FINDINGS: In total, 93 (86.9%) of 107 patients randomized to zonisamide and 90 (90.0%) of 100 patients randomized to placebo completed the trial. Responder rates were 50% for zonisamide versus 31% for placebo (p = 0.0044; intention-to-treat population, last observation carried forward). The overall incidence of TEAEs was similar for zonisamide (55.1%) versus placebo (50.0%), with low rates of serious TEAEs with zonisamide and placebo (3.7% vs. 2.0%) and TEAEs leading to withdrawal (0.9% vs. 3.0%). TEAEs reported more frequently with zonisamide versus placebo were decreased appetite (6.5% vs. 4.0%), decreased weight (4.7% vs. 3.0%), somnolence (4.7% vs. 2.0%), vomiting (3.7% vs. 2.0%), and diarrhea (3.7% vs. 1.0%). SIGNIFICANCE: Adjunctive zonisamide treatment was shown to be effective and well tolerated in pediatric patients with partial epilepsy. No new or unexpected safety findings emerged.
|
Authors | Renzo Guerrini, Anna Rosati, Joanna Segieth, Simona Pellacani, Kate Bradshaw, Luigi Giorgi |
Journal | Epilepsia
(Epilepsia)
Vol. 54
Issue 8
Pg. 1473-80
(Aug 2013)
ISSN: 1528-1167 [Electronic] United States |
PMID | 23837461
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Wiley Periodicals, Inc. © 2013 International League Against Epilepsy. |
Chemical References |
- Anticonvulsants
- Isoxazoles
- Zonisamide
|
Topics |
- Adolescent
- Anticonvulsants
(therapeutic use)
- Child
- Double-Blind Method
- Drug Therapy, Combination
- Epilepsies, Partial
(drug therapy)
- Female
- Humans
- Isoxazoles
(therapeutic use)
- Male
- Treatment Outcome
- Zonisamide
|